OR03-1 The Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis and Osteoarthritis

Abaloparatide (ABL) is a novel, selective activator of the PTH1 receptor signaling pathway. In the 18-month Phase 3 ACTIVE study in women with postmenopausal osteoporosis (OP) (NCT01343004), ABL significantly increased bone mineral density (BMD), and decreased the risk of new vertebral (VF), nonvert...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Endocr Soc
Main Authors: Lane, Nancy, Mitlak, Bruce, Weiss, Richard, Wang, Yamei, Valenzuela, Guillermo, Bilezikian, John
Formato: Artigo
Idioma:Inglês
Publicado em: Endocrine Society 2019
Assuntos:
Bone and Mineral Metabolism
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6554836/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-OR03-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados